title: Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes.
abstract: The optical properties of a receptor-targeted probe designed for dual-modality mapping of the sentinel lymph node (SLN) was optimized. Specific fluorescence brightness was used as the design criterion, which was defined as the fluorescence brightness per mole of the contrast agent. Adjusting the molar ratio of the coupling reactants, IRDye 800CW-NHS-ester and tilmanocept, enabled us to control the number of fluorescent molecules attached to each tilmanocept, which was quantified by H1 nuclear magnetic resonance spectroscopy. Quantum yields and molar absorptivities were measured for unconjugated IRDye 800CW and IRDye 800CW-tilmanocept (800CW-tilmanocept) preparations at 0.7, 1.5, 2.3, 2.9, and 3.8 dyes per tilmanocept. Specific fluorescence brightness was calculated by multiplication of the quantum yield by the molar absorptivity and the number of dyes per tilmanocept. It predicted that the preparation with 2.3 dyes per tilmanocept would exhibit the brightest signal, which was confirmed by fluorescence intensity measurements using three optical imaging systems. When radiolabeled with Ga68 and injected into the footpads of mice, the probe identified SLNs by both fluorescence and positron emission tomography (PET) while maintaining high percent extraction by the SLN. These studies demonstrated the feasibility of 800CW-tilmanocept for multimodal SLN mapping via fluorescence and PET-computed tomography imaging.
authors: University of California, San Diego, Department of Chemistry, La Jolla, California 92093, USA.
authors: Zhengtao
authors: Z
authors: Qin
authors: David J
authors: DJ
authors: Hall
authors: Michael A
authors: MA
authors: Liss
authors: Carl K
authors: CK
authors: Hoh
authors: Christopher J
authors: CJ
authors: Kane
authors: Anne M
authors: AM
authors: Wallace
authors: David R
authors: DR
authors: Vera
mesh_terms: D000818:Animals; D003911:Dextrans / Q000032:analysis / Q000737:chemistry / Q000493:pharmacokinetics; D005260:Female; D005456:Fluorescent Dyes / Q000032:analysis / Q000737:chemistry / Q000493:pharmacokinetics; D008198:Lymph Nodes / Q000737:chemistry* / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D057054:Molecular Imaging / Q000379:methods*; D061848:Optical Imaging / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000032:analysis / Q000737:chemistry / Q000493:pharmacokinetics; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D016284:Technetium Tc 99m Pentetate / Q000031:analogs & derivatives / Q000032:analysis / Q000737:chemistry / Q000493:pharmacokinetics
chemical_list: D003911:Dextrans; D005456:Fluorescent Dyes; D019275:Radiopharmaceuticals; C577481:gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran; D016284:Technetium Tc 99m Pentetate
references: Eur Urol. 2011 Oct;60(4):826-33
references: 21458154
references: Bioconjug Chem. 2000 Sep-Oct;11(5):696-704
references: 10995214
references: J Nucl Med. 1989 Sep;30(9):1519-30
references: 2549225
references: Chem Rev. 2000 Jun 14;100(6):1973-2012
references: 11749281
references: Fed Proc. 1957 Jul;16(2):suppl 3-6
references: 13461941
references: J Nucl Med. 2012 Jul;53(7):1034-40
references: 22645297
references: Prostate Cancer Prostatic Dis. 2008;11(4):320-4
references: 18490935
references: Nucl Med Biol. 2005 Oct;32(7):687-93
references: 16243643
references: Clin Exp Metastasis. 2012 Oct;29(7):673-80
references: 22714690
references: Cancer. 1977 Feb;39(2):456-66
references: 837331
references: Semin Oncol. 2007 Dec;34(6):498-508
references: 18083373
references: Ann Surg Oncol. 2007 Feb;14(2):913-21
references: 17146742
references: Bioconjug Chem. 2010 Oct 20;21(10):1811-9
references: 20873712
references: Ann Surg. 2005 Sep;242(3):302-11; discussion 311-3
references: 16135917
references: Ann Surg Oncol. 2013 Feb;20(2):680-8
references: 23054107
references: Ann Surg Oncol. 2003 Jun;10(5):531-8
references: 12794019
references: Nucl Med Biol. 2008 Jul;35(5):523-7
references: 18589295
references: Br J Surg. 2010 May;97(5):737-43
references: 20309948
references: J Am Coll Surg. 2011 Jun;212(6):e33-9
references: 21450495
references: Bioorg Med Chem. 2011 Jun 15;19(12):3769-76
references: 21612930
references: J Nucl Med. 2001 Jun;42(6):951-9
references: 11390562
references: Radiology. 2012 Oct;265(1):186-93
references: 22753678
references: Arch Surg. 1992 Apr;127(4):392-9
references: 1558490
references: Ann Surg. 1996 Feb;223(2):217-24
references: 8597518
references: Proc Staff Meet Mayo Clin. 1957 Sep 4;32(18):478-84
references: 13465828
references: Ann Surg Oncol. 2011 Apr;18(4):961-9
references: 21331809
references: Ann Surg Oncol. 2013 Aug;20(8):2590-9
references: 23504141
references: Angew Chem Int Ed Engl. 2011 Jul 4;50(28):6258-63
references: 21656624
references: J Nucl Med. 1979 Oct;20(10):1038-46
references: 231640
references: Surg Oncol. 1993;2(3):137-43
references: 8252203